“Natural”, “modified natural”, “mild”, “mini” and “minimal stimulation” are often used as if they describe one treatment. They do not. The medication, monitoring, cancellation risk and laboratory pathway can differ considerably, so the label is less important than the protocol written underneath it.

My interest in lower-intensity protocols developed during my training at C.Re.A.Te Fertility in London with Professors Geeta Nargund and Stuart Campbell. The practical question is how much stimulation is useful for this patient, in this cycle, for this goal.

1. What natural, modified natural and mild IVF mean

There is no single universally accepted dose that turns “mild” into “conventional”. Ask for the starting dose, expected duration, ovulation-control medicine, trigger plan and the number of follicles the clinician realistically expects. A marketing term cannot replace those details.

2. The ovarian response sets the ceiling

Stimulation recruits follicles that are available in that cycle; it does not manufacture a new ovarian reserve. AMH and antral follicle count help estimate likely egg yield, while age remains central to the probability that an egg is chromosomally competent. Neither test can predict an individual embryo or guarantee the outcome of one cycle.

For a predicted normal responder, increasing stimulation within a sensible range may recruit a useful cohort. For someone with very low reserve or a repeated poor response, escalating the dose may add cost and side effects without producing a proportionate increase in mature eggs. Higher doses can sometimes increase egg numbers, but the evidence does not show that continually increasing the dose reliably improves live birth.

Current ESHRE guidance does not recommend gonadotrophin doses above 300 IU for predicted low responders. It also does not recommend modified natural cycle routinely over conventional stimulation for all low responders, while recognising that clinicians may consider it when ovarian reserve is extremely low. That distinction matters: “reasonable for a selected patient” is not the same as “proven superior”.

3. Who may genuinely benefit

A lower-intensity approach is most defensible when it solves a specific problem rather than expressing a general preference for everything “natural”.

• Very low ovarian reserve or previous poor response. If high-dose cycles repeatedly produce one or two mature eggs, a milder strategy may offer a similar practical opportunity with less medication. Previous cycle data matter more than the label “low AMH” alone.
• High sensitivity to stimulation or concern about OHSS. Mild stimulation can reduce exposure and the number of developing follicles. A strict natural cycle largely avoids stimulation-related OHSS.
• Patients who cannot or do not wish to use higher doses. Medical history, tolerability, cost or informed preference may justify a lower-intensity plan.
• Patients prepared for single- or low-egg cycles. Natural treatment can make sense when the patient accepts the risk that no transfer will follow.
• Selected fertility-preservation or embryo-accumulation plans. In some circumstances, repeated lower-intensity retrievals may be discussed, but the time, cost and attrition across cycles must be explicit.

The important phrase is “may benefit”. A low AMH result does not automatically prescribe natural IVF, just as one disappointing response does not prove that conventional stimulation can never work.

4. Who these approaches may not suit

Natural-cycle IVF is a fragile pathway because one follicle carries the whole cycle. Premature ovulation, an inaccessible follicle, no egg at retrieval, an immature egg, failed fertilisation or arrested embryo development can mean there is no transfer. That may be an acceptable trade-off for one patient and unacceptable for another.

Natural or very mild treatment may be a poor fit when:

• a normal response is expected and creating several embryo opportunities is important;
• there is limited time and repeated low-yield cycles could delay the chance of transfer;
• preimplantation genetic testing is planned and several blastocysts may be needed to obtain an informative result;
• severe sperm factors or previous fertilisation failure make reliance on one oocyte especially precarious;
• the patient finds the possibility of repeated cancellations more burdensome than medication;
• a fertility-preservation goal requires efficient accumulation of mature eggs.

Conversely, conventional stimulation is not automatically wrong for a poor responder. A carefully chosen antagonist protocol may provide more mature eggs in some cycles, and even one additional embryo can matter. The decision should use previous response, age, reserve, sperm, treatment history and priorities rather than ideology.

5. OHSS risk, side effects and treatment burden

Ovarian hyperstimulation syndrome is driven by the response to stimulation and the final-maturation trigger. Natural-cycle IVF avoids the multi-follicular response that causes stimulation-related OHSS. Mild stimulation generally lowers the risk by recruiting fewer follicles, but it does not make risk zero.

Modern OHSS prevention is broader than simply lowering the starting dose. For patients at increased risk, clinicians may use an antagonist protocol, adjust doses according to response, choose a GnRH-agonist trigger where appropriate, avoid hCG exposure and freeze embryos for later transfer. A patient with polycystic ovaries may benefit from a risk-reduction strategy without necessarily needing natural-cycle IVF.

Burden includes injections, scans, time away from work, cost and emotional recovery. Mild cycles are often shorter and use less medication, but repeated monitoring and cancellation can create a different burden.

6. How to judge success by more than egg count

Egg count is an intermediate result, not the final outcome. A fair comparison between protocols should consider:

For a poor responder, retrieving two mature eggs with a tolerable protocol may be a good result even if another clinic advertises much larger average egg numbers. For a normal responder seeking embryo banking, deliberately limiting the cohort may reduce cumulative opportunity. The same egg count has different meaning in different patients.

7. What the evidence does not support

• Low medication does not reverse age-related chromosome changes in eggs.
• High-dose stimulation does not “use up” future eggs in the simplistic way sometimes claimed; it recruits follicles from that cycle’s available cohort.
• Natural-cycle IVF is not proven to improve implantation merely because hormone levels are lower.
• Mild stimulation does not guarantee a better-quality embryo, and conventional stimulation does not automatically damage egg quality.
• A protocol should not be called successful because it produced fewer injections while ignoring cancellation, no-transfer and time-to-pregnancy rates.

Randomised evidence does not show a clear live-birth advantage for mild treatment across all patients. It supports lower medication use and, in normal and high responders, lower OHSS risk. For low responders, the question is whether extra medication creates enough extra opportunity to justify its burden.

8. A practical way to choose

Ask the clinician to compare two real protocols for you rather than discuss philosophies. The comparison should state the expected follicle range, daily dose, likely medication cost, cancellation risk, trigger, fertilisation plan and what would prompt conversion, freezing or stopping.

Fees are a guide only. Clinic and laboratory fees exclude medication unless a written quotation states otherwise.

Then ask one final question: “If my response is exactly what you predict, why is this strategy more likely to help me reach a live birth than the alternative?” The answer should acknowledge uncertainty and show how your previous cycles informed the choice.

Medical disclaimer: This article is for general education and does not replace individual medical advice, diagnosis or treatment. Ovarian-stimulation choice, medicine dose, trigger, retrieval and embryo strategy must be based on your history, examination and current results. Do not start, stop or alter fertility medication without instructions from your treating clinician.